JAMA Neurol:远程医疗对院前卒中患者的评估和治疗效果

2015-12-29 phylis 译 MedSci原创

背景:现场治疗处理团队的移动卒中治疗单元(MSTUs)包括可以提供溶栓的血管神经医师。这个单元可以高效利用资源,如果可以依赖远程医疗的话,可以减少对现场神经科医生的需要。

背景:现场治疗处理团队的移动卒中治疗单元(MSTUs)包括可以提供溶栓的血管神经医师。这个单元可以高效利用资源,如果可以依赖远程医疗的话,可以减少对现场神经科医生的需要。

目标:为了测试远程医疗是否是可靠的,以及远程医疗存在对MSTU进行急性卒中治疗是否是足够的。

设计,设置和参与者:2014年7月18日至11月1日间进行的前瞻性观察研究。研究分析的日期是2014年11月1日到2015年3月30日。这是一个以社区为基础的研究,评估俄亥俄州,克利夫兰MSTU中远程医疗的应用。在克利夫兰诊所MSTU项目实施后,受试者是克利夫兰首批100在早上8点和晚上8点之间的脑卒中样症状的急性发作的居民,并进行MSTU评估。血管神经科医师通过远程医疗评估前100患者、神经影像科医生通过CT扫描后对脑影像进行远程评估。医疗记录数据,并将数据记录到一个前瞻性注册表。

主要成果和措施:研究比较了同年,MSTU治疗的患者和通过急诊进行急诊部治疗的患者。记录了患者从发病到进入MSTU治疗或急诊部治疗的患者,并且记录在评估过程中遇到的问题。

结果:成功评估了99/100名患者。远程医疗评估时间的中位数为20分钟(IQR,14-27分钟)。一个患者由于联系的失误被运送到最近的急诊科。6名患者远程医疗联接失败,但持续未超过60秒,临床护理并未受到影响。MSTU组从开始到CT完成时间(13分钟,IQR :9-21分钟),从开始到静脉溶栓(32分钟, IQR 24-47分钟)的时间短于对照组(18分钟,IQR:12-26分钟)和( 58分钟,IQR:53-68分钟)。对CT的判断的时间,两组间没有差异。

结论与相关性:MSTU中应用远程医疗是可行的,技术失败率较低,并且为降低系统成本提供了途径。

原文出处:

Itrat A, Taqui A, et al. Telemedicine in Prehospital Stroke Evaluation and Thrombolysis: Taking Stroke Treatment to the Doorstep.  JAMA Neurol. 2015 Dec 7.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1720088, encodeId=b8321e2008825, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Nov 02 23:09:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769939, encodeId=5e801e6993960, content=<a href='/topic/show?id=51469830949' target=_blank style='color:#2F92EE;'>#院前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98309, encryptionId=51469830949, topicName=院前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5ca38130612, createdName=mhzhuang@stu.e, createdTime=Wed Sep 28 09:09:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999627, encodeId=0616199962e23, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Mar 08 09:09:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893905, encodeId=a782189390593, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Oct 23 11:09:00 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61970, encodeId=97a4619e0c2, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Jan 29 08:38:00 CST 2016, time=2016-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58024, encodeId=e8c95802400, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da3d1626631, createdName=1dd7d1dam20(暂无匿称), createdTime=Sat Jan 16 22:09:00 CST 2016, time=2016-01-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1720088, encodeId=b8321e2008825, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Nov 02 23:09:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769939, encodeId=5e801e6993960, content=<a href='/topic/show?id=51469830949' target=_blank style='color:#2F92EE;'>#院前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98309, encryptionId=51469830949, topicName=院前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5ca38130612, createdName=mhzhuang@stu.e, createdTime=Wed Sep 28 09:09:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999627, encodeId=0616199962e23, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Mar 08 09:09:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893905, encodeId=a782189390593, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Oct 23 11:09:00 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61970, encodeId=97a4619e0c2, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Jan 29 08:38:00 CST 2016, time=2016-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58024, encodeId=e8c95802400, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da3d1626631, createdName=1dd7d1dam20(暂无匿称), createdTime=Sat Jan 16 22:09:00 CST 2016, time=2016-01-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1720088, encodeId=b8321e2008825, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Nov 02 23:09:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769939, encodeId=5e801e6993960, content=<a href='/topic/show?id=51469830949' target=_blank style='color:#2F92EE;'>#院前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98309, encryptionId=51469830949, topicName=院前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5ca38130612, createdName=mhzhuang@stu.e, createdTime=Wed Sep 28 09:09:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999627, encodeId=0616199962e23, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Mar 08 09:09:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893905, encodeId=a782189390593, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Oct 23 11:09:00 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61970, encodeId=97a4619e0c2, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Jan 29 08:38:00 CST 2016, time=2016-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58024, encodeId=e8c95802400, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da3d1626631, createdName=1dd7d1dam20(暂无匿称), createdTime=Sat Jan 16 22:09:00 CST 2016, time=2016-01-16, status=1, ipAttribution=)]
    2016-03-08 yinhl1978
  4. [GetPortalCommentsPageByObjectIdResponse(id=1720088, encodeId=b8321e2008825, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Nov 02 23:09:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769939, encodeId=5e801e6993960, content=<a href='/topic/show?id=51469830949' target=_blank style='color:#2F92EE;'>#院前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98309, encryptionId=51469830949, topicName=院前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5ca38130612, createdName=mhzhuang@stu.e, createdTime=Wed Sep 28 09:09:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999627, encodeId=0616199962e23, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Mar 08 09:09:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893905, encodeId=a782189390593, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Oct 23 11:09:00 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61970, encodeId=97a4619e0c2, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Jan 29 08:38:00 CST 2016, time=2016-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58024, encodeId=e8c95802400, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da3d1626631, createdName=1dd7d1dam20(暂无匿称), createdTime=Sat Jan 16 22:09:00 CST 2016, time=2016-01-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1720088, encodeId=b8321e2008825, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Nov 02 23:09:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769939, encodeId=5e801e6993960, content=<a href='/topic/show?id=51469830949' target=_blank style='color:#2F92EE;'>#院前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98309, encryptionId=51469830949, topicName=院前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5ca38130612, createdName=mhzhuang@stu.e, createdTime=Wed Sep 28 09:09:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999627, encodeId=0616199962e23, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Mar 08 09:09:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893905, encodeId=a782189390593, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Oct 23 11:09:00 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61970, encodeId=97a4619e0c2, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Jan 29 08:38:00 CST 2016, time=2016-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58024, encodeId=e8c95802400, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da3d1626631, createdName=1dd7d1dam20(暂无匿称), createdTime=Sat Jan 16 22:09:00 CST 2016, time=2016-01-16, status=1, ipAttribution=)]
    2016-01-29 1dd8a7c5m95(暂无匿称)

    学习!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1720088, encodeId=b8321e2008825, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Nov 02 23:09:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769939, encodeId=5e801e6993960, content=<a href='/topic/show?id=51469830949' target=_blank style='color:#2F92EE;'>#院前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98309, encryptionId=51469830949, topicName=院前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5ca38130612, createdName=mhzhuang@stu.e, createdTime=Wed Sep 28 09:09:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999627, encodeId=0616199962e23, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Mar 08 09:09:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893905, encodeId=a782189390593, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Oct 23 11:09:00 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61970, encodeId=97a4619e0c2, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Jan 29 08:38:00 CST 2016, time=2016-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58024, encodeId=e8c95802400, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da3d1626631, createdName=1dd7d1dam20(暂无匿称), createdTime=Sat Jan 16 22:09:00 CST 2016, time=2016-01-16, status=1, ipAttribution=)]
    2016-01-16 1dd7d1dam20(暂无匿称)

    了解

    0

相关资讯

Medicine :胆囊息肉可能是卒中发生的风险因素

共同的代谢性疾病是胆囊息肉(GP)和卒中的危险因素。研究者评估GP和卒中风险的关系。2000年到2011年,从纵向健康保险数据库2000中识别20岁以上的GP患者。在15975个检查的患者中,12780名非GP患者,3195名为GP患者。校正年龄,性别和共发病后,应用Cox比例风险模型评估卒中发生的相对风险。与非GP组相比,GP患者发生卒中的风险较高(6.66 vs 5.20/1000人年),其发

Stroke:卒中后迷走神经刺激配合康复治疗是安全可行的

背景和目的:最近动物研究表明,迷走神经刺激(VNS)配合运动可以改善运动特定的可塑性和卒中后前肢的运动功能。研究者进行了一项随机对照试验研究VNS配合康复对缺血性脑卒中上肢功能的影响。方法:21名缺血性卒中发生超过6个月的受试者,这些受试者存在中到重度的上肢功能损伤,将其随机分为VNS配合康复训练组,或者仅接受康复训练。康复包括每周3次两小时训练,每次涉及超过400运动试验。在VNS组,运动配合0

Neurology: HIV感染、相关治疗及高血压可增加卒中发生的风险

目的:探讨HIV,相关治疗和高血压是否是马拉维人群中卒中的危险因素。方法:研究者进行了一项病例对照研究,222名急性卒中患者,应用全球位置系统随机选择,按照年龄,性别和居住地与卒中组患者进行配对,共有503名对照组受试者。应用多变量logistic回归模型进行病例对照之间的比较。结果:HIV感染(人群归因分数[ PAF ] 15%)和高血压(PAF 46%)与脑卒中发生密切相关。HIV是年轻脑卒中

Neuroscience:患者发生卒中后,警惕出现学习功能障碍

认为学习能力支持卒中后的恢复和康复治疗。因此,学习障碍可能会减少恢复的潜力。这里,研究者提出假设,卒中幸存者存在反馈驱动内隐学习障碍。卒中幸存者30例和按照年龄配对的健康对照组21例,受试者学习分类任务,同时对亚组进行功能磁共振扫描(17卒中患者,10名对照患者)。卒中人员学习分类线索比对照组慢。奖励一个笑脸后,当重复这个线索时,卒中幸存者不太可能给出相同的反应。与对照组相比,脑卒中患者苍白球,丘

Clin Lab:卒中类型不同,血脂代谢不同

背景:越来越多的流行病学研究已经确定了血脂异常与动脉粥样硬化性卒中之间的关系密切。的确,脂类代谢在不同的卒中类型中存在差异。有关特定类型的缺血性卒中的危险因素的研究较少,尤其是,有关血脂异常的作用的证据较少。本研究旨在确定急性缺血性卒中类型和血脂水平的关系。方法:检测362例缺血性脑卒中患者和181例健康对照者血脂,包括TC、TG、LDL-C、HDL-C、ApoA、ApoB、ApoE水平和LP(a

Medicine:甘露醇治疗记性卒中并发急性肾损伤的危险因素

甘露醇是一种渗透利尿,常用于治疗急性脑水肿,但应用甘露醇也能增加急性肾损伤(AKI)的风险。这项研究中,研究者调查急性卒中患者甘露醇相关AKI的发生及危险因素。共有432名患者(缺血性卒中62.3%)进入三甲医院重症监护中心接受甘露醇治疗纳入研究。临床指标包括入院NIHSS分数,血管危险因素,实验室数据及并发肾毒性药物注册。急性肾损伤的定义为血清肌酐(SCr)绝对升高≥0.3 mg/ml或者SCr